Abstract Combine supplements of OptiPEAK T Lymphocyte media. Isolate human T lymphocytes from whole blood. Wash to remove traces of donor serum. Activate and expand T lymphocytes (7-10 days) in OptiPEAK T Lymphocyte serum free media. Harvest T lymphocytes. Perform post- expansion, flow cytometric analysis of phenotypic surface markers. Introduction Human T Cell expansion has …
Abstract Utilization of classical adherent formats in large scale viral vector manufacturing can have significant setbacks due to the lack of scalability of production vessels typically used at small scale. The iCELLis fixed bed bioreactor has emerged as an enabling technology to efficiently scale adherent-based processes in a controlled and highly integrated environment. This technology …
Production of Adenoviral Associated Viral Vectors Introduction Adenoviral associated viral (AAV) vectors used in gene therapy have received notable attention considering the recent clinical successes. Traditionally, production of these vectors is achieved by triple transient transfection using the adherent HEK293 cell line in fetal bovine serum (FBS)-supplemented basal media, such as DMEM. The basal …
An Interview with Marcus Curl, Director of Product Applications Can you start by providing a quick introduction to InVitria and how you provide value to biopharmaceutical manufacturing? InVitria provides an alternative to serum and serum-proteins in the production and formulation of therapeutics. We specialize in creating completely blood component-free manufacturing environments for gene therapy, cell …
Recombinant Human Serum Albumin Excipient – Regulatory Filing and Approval for Use in Vaccine Manufacturing During the 2020 Excipient World Conference & Expo, supported by IPEC-Americas, Kara Quinn, the Associate Director of Engineering for Merck & Co, presented an online seminar detailing the first-hand account of the complex process of regulatory agency filing that led …
